David M Peereboom
Overview
Explore the profile of David M Peereboom including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
2182
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee E, Alexander B, Romo C, Supko J, Agar N, Talebi Z, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39820282
Purpose: Adavosertib is an oral small molecular inhibitor of Wee1. The Adult Brain Tumor Consortium performed a phase I study of adavosertib, radiation (RT) and temozolomide (TMZ) in newly diagnosed...
2.
Ahluwalia M, Ozair A, Rudek M, Ye X, Holdhoff M, Lieberman F, et al.
Cell Rep Med
. 2024 Jul;
5(7):101630.
PMID: 38955178
Recurrent high-grade gliomas (rHGGs) have a dismal prognosis, where the maximum tolerated dose (MTD) of IV terameprocol (5 days/month), a transcriptional inhibitor of specificity protein 1 (Sp1)-regulated proteins, is 1,700 ...
3.
4.
Ahluwalia M, Ozair A, Drappatz J, Ye X, Peng S, Lee M, et al.
Clin Cancer Res
. 2024 Jun;
30(15):3167-3178.
PMID: 38836759
Purpose: Patients with glioblastoma (GBM) have a dismal prognosis. Although the DNA alkylating agent temozolomide (TMZ) is the mainstay of chemotherapy, therapeutic resistance rapidly develops in patients. Base excision repair...
5.
Barnett A, Ozair A, Bamashmos A, Li H, Bosler D, Yeaney G, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38611052
: Sex differences in glioblastoma (GBM) have been observed in incidence, genetic and epigenetic alterations, and immune response. These differences have extended to the methylation of the MGMT promoter, which...
6.
Bussies P, Chau D, Hunt J, Policarpio-Nicolas M, Friedman C, McKenney J, et al.
Gynecol Oncol Rep
. 2023 Oct;
49:101279.
PMID: 37840845
•First report of a secondary somatic glioblastoma arising from MCT-MT in a patient with underlying Li-Fraumeni syndrome.•The rarity of glioblastoma arising from MCT-MT warrants investigation for underlying genetic predisposition.•Glioblastomas arising...
7.
Ahluwalia M, Rogers L, Chaudhary R, Newton H, Ozair A, Khosla A, et al.
Commun Med (Lond)
. 2023 Sep;
3(1):120.
PMID: 37684373
Background: Glioblastoma (GBM), the most lethal primary brain tumor, has limited treatment options upon recurrence after chemoradiation and bevacizumab. TRC105 (carotuximab), a chimeric anti-endoglin (CD105) antibody, inhibits angiogenesis and potentiates...
8.
Kim I, Winter K, Sperduto P, De Los Santos J, Peereboom D, Ogunleye T, et al.
Int J Radiat Oncol Biol Phys
. 2023 Jul;
118(5):1391-1401.
PMID: 37506981
Purpose: Lapatinib plus whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS) was hypothesized to improve the 12-week intracranial complete response (CR) rate compared with either option of radiation therapy...
9.
Tom M, DiFilippo F, Jones S, Suh J, Obuchowski N, Smile T, et al.
J Neurooncol
. 2023 Jun;
163(3):647-655.
PMID: 37341842
Purpose: Distinguishing radiation necrosis from tumor progression among patients with brain metastases previously treated with stereotactic radiosurgery represents a common diagnostic challenge. We performed a prospective pilot study to determine...
10.
Tatineni V, OShea P, Saxena S, Khosla A, Ozair A, Kotecha R, et al.
Cancers (Basel)
. 2023 Jun;
15(11).
PMID: 37296975
Introduction: Traditionally, brain metastases have been treated with stereotactic radiosurgery (SRS), whole-brain radiation (WBRT), and/or surgical resection. Non-small cell lung cancers (NSCLC), over half of which carry EGFR mutations, are...